Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.
about
The European Haemophilia Network (EUHANET)Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activityLarge scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.Enhancing haemophilia care through registries.The role of previously untreated patient studies in understanding the development of FVIII inhibitors.Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor.Safety surveillance in haemophilia and allied disorders.Real-life evidence in evaluating effectiveness of treatment in Haemophilia A with a recombinant FVIII concentrate: a non-interventional study in emerging countries.BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
P2860
Q27001556-C504FE51-7855-4C4A-B8AB-8C10595E966CQ28487387-122B0AD6-89C4-4B5C-A77D-E952E14DF91CQ30234910-E8334F99-1731-4E8B-9F8A-10F0F7F0672FQ34580100-D9F1782D-664D-4855-9AE5-2E48BA180367Q37185097-E1B2AFEE-64EC-4676-8F96-D198D4454E32Q37253340-D883E749-50B6-4255-91FD-2535879E98D3Q38206861-340D70BE-CF84-43BE-93B7-C20266399A97Q38575475-D3A67AEB-BF36-4312-82FD-B3AA4DF0A2AAQ38722283-7EF744C1-F1C4-4425-B5CC-A49F1A3422BCQ38784133-47CEEDC6-1FE5-4F3A-8FDC-E86D9C2F4583Q41504794-4E4EF525-2F4A-4EDF-8412-8AD1763B7E9CQ45865134-610CBC9D-1E78-4469-B366-5D2B990E3FCEQ45875541-41B0A825-1FE4-40D7-A0B4-A6B63AB814E0Q45882197-A0AA70B7-AF7F-41FF-B72E-6B47A951CC8A
P2860
Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Validity of assessing inhibito ...... stry data: the EUHASS project.
@ast
Validity of assessing inhibito ...... stry data: the EUHASS project.
@en
Validity of assessing inhibito ...... stry data: the EUHASS project.
@nl
type
label
Validity of assessing inhibito ...... stry data: the EUHASS project.
@ast
Validity of assessing inhibito ...... stry data: the EUHASS project.
@en
Validity of assessing inhibito ...... stry data: the EUHASS project.
@nl
prefLabel
Validity of assessing inhibito ...... stry data: the EUHASS project.
@ast
Validity of assessing inhibito ...... stry data: the EUHASS project.
@en
Validity of assessing inhibito ...... stry data: the EUHASS project.
@nl
P2093
P2860
P1433
P1476
Validity of assessing inhibito ...... stry data: the EUHASS project.
@en
P2093
D Lewandowski
H Marijke van den Berg
M P Janssen
P2860
P304
P356
10.1111/J.1365-2516.2011.02687.X
P577
2011-11-02T00:00:00Z